作者: Derek A. Wainwright , Irina V. Balyasnikova , Yu Han , Maciej S. Lesniak
DOI: 10.1016/J.YEXMP.2011.04.012
关键词: Glioma 、 Multiple myeloma 、 Brain tumor 、 Lung cancer 、 Biology 、 Astrocytoma 、 Genetic enhancement 、 CD137 、 Pathology 、 Immunotherapy
摘要: Abstract Glioblastoma multiforme (grade IV astrocytoma) is a highly malignant brain tumor with poor treatment options and an average lifespan of 15 months after diagnosis. Previous work has demonstrated that BST2 (bone marrow stromal cell antigen 2; also known as PDCA-1, CD137 HM1.24) expressed by multiple myeloma, endometrial cancer primary lung cells. on the plasma membrane, which makes it ideal target for immunotherapy. Accordingly, several groups have shown mAb to be effective targeting In this report, we hypothesized in human mouse tumors plays critical role progression. We show expression upregulated at both mRNA protein level high grade when compared low astrocytoma ( p